Donovan Joanne M. 4
4 · Edgewise Therapeutics, Inc. · Filed Mar 31, 2026
Research Summary
AI-generated summary of this filing
Edgewise (EWTX) CMO Joanne M. Donovan Exercises Options, Sells Shares
What Happened
Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (EWTX), exercised 21,338 stock options and immediately sold the 21,338 shares on March 31, 2026. The options were exercised at an average strike of $7.08 per share (total cost $151,073). The shares were sold in the open market at an average price of $32.12 per share for gross proceeds of approximately $685,308, implying roughly $534,235 in proceeds over the exercise cost before taxes and fees. The underlying option position was then cancelled/converted (reported as a derivative disposition).
Key Details
- Transaction date: 2026-03-31 (Form 4 filed same day).
- Exercise: 21,338 shares exercised at $7.08 each; total exercise cost $151,073.
- Sale: 21,338 shares sold at an average price of $32.12; gross proceeds ~$685,308. Sale prices ranged $32.00–$32.35 (average reported).
- Net proceeds before taxes/fees (approx): $685,308 − $151,073 = $534,235.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes of note: sale was executed under a Rule 10b5-1 trading plan adopted Dec 26, 2025; option vesting schedule noted (1/48th vests monthly beginning Sept 17, 2023).
- Filing timeliness: Form 4 filed on the same date as the transactions (2026-03-31).
Context
This was an option exercise followed by an immediate sale of the acquired shares (a cashless-like transaction in practice). The separate derivative disposal line at $0.00 represents cancellation/conversion of the option instrument after exercise. The sale was executed under a pre-established 10b5-1 plan, which is commonly used to schedule insider sales and can limit inferences about timing or intent.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-03-31$7.08/sh+21,338$151,073→ 30,935 total - Sale
Common Stock
[F1][F2]2026-03-31$32.12/sh−21,338$685,308→ 9,597 total - Exercise/Conversion
Stock Option (Right to Buy)
[F3]2026-03-31−21,338→ 153,662 totalExercise: $7.08Exp: 2033-08-17→ Common Stock (21,338 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.
- [F2]The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.